Skip to main content

INVESTIGACION TRASLACIONAL EN ENFERMEDADES RARAS DE ORIGEN VASCULAR: MODELOS PATOLOGICOS Y BASES MOLECULARES DE LA TERAPIA

PID2020-115371RB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2020
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Drug repurposing as a current strategy in medicine discovery, Reposicionamiento de fármacos como estrategia en la búsqueda de nuevas terapias

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A Novel Splicing Mutation in the ACVRL1/ALK1 Gene as a Cause of HHT2

  • Errasti, Suriel
  • Peñalva, Mercedes
  • Recio-Poveda, Lucía
  • Vilches, Susana
  • Casado-Vela, Juan
  • Pérez Pérez, Julián
  • Botella, Luisa María
  • Albiñana, Virginia
  • Cuesta, Ángel M.
Hereditary Hemorrhagic Telangiectasia (HHT) is a rare disorder of vascular development. Common manifestations include epistaxis, telangiectasias and arteriovenous malformations in multiple organs. Different deletions or nonsense mutations have been described in the ENG (HHT1) or ACVRL1/ALK1 (HHT2) genes, all affecting endothelial homeostasis. A novel mutation in ACVRL1/ALK1 has been identified in a Peruvian family with a clinical history compatible to HHT. Subsequently, 23 DNA samples from oral exchanges (buccal swaps) of the immediate family members were analyzed together with their clinical histories. A routine cDNA PCR followed by comparative DNA sequencing between the founder and another healthy family member showed the presence of the aforementioned specific mutation. The single mutation detected (c.525 + 1G > T) affects the consensus splice junction immediately after exon 4, provokes anomalous splicing and leads to the inclusion of intron IV between exons 4 and 5 in the ACVRL1/ALK1 mRNA and, therefore, to ALK1 haploinsufficiency. Complete sequencing determined that 10 of the 25 family members analyzed were affected by the same mutation. Notably, the approach described in this report could be used as a diagnostic technique, easily incorporated in clinical practice in developing countries and easily extrapolated to other patients carrying such a mutation., This research was funded by MINECO (Ministry of Economy of Spain), grant number SAF2017-83351R, and by MICINN (Ministry of Science and Innovation of Spain), grant number PID2020-115371RB-I00. LR-P was the recipient of a contract from an internal project of CSIC (PIE201820E073)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Mutation in Chek2 triggers von Hippel-Lindau hemangioblastoma growth

  • Cabrera-Montes, Jorge
  • Aguirre, Daniel T.
  • Viñas-López, Jesús
  • Lorente-Herraiz, Laura
  • Recio-Poveda, Lucía
  • Albiñana, Virginia
  • Pérez Pérez, Julián
  • Botella, Luisa María
  • Cuesta, Ángel M.
Purpose: Von Hippel-Lindau (VHL) is a rare inherited disease mainly characterized by the growth of tumours, predominantly hemangioblastomas (Hbs) in the CNS and retina, and renal carcinomas. The natural history of VHL disease is variable, differing in the age of onset and its penetrance, even among relatives. Unfortunately, sometimes VHL shows more severe than average: the onset starts in adolescence, and surgeries are required almost every year. In these cases, the factor that triggers the appearance and growth of Hbs usually remains unknown, although additional mutations are suspected., Methods: We present the case of a VHL patient whose first surgery was at 13 years of age. Then, along his next 8 years, he has undergone 5 surgeries for resection of 10 CNS Hbs. To clarify this severe VHL condition, DNA from a CNS Hb and white blood cells (WBC) was sequenced using next-generation sequencing technology., Results: Massive DNA sequencing of the WBC (germ line) revealed a pathogenic mutation in CHEK2 and the complete loss of a VHL allele (both tumour suppressors). Moreover, in the tumour sample, several mutations, in BRAF1 and PTPN11 were found. Familiar segregation studies showed that CHEK2 mutation was in the maternal lineage, while VHL was inherited by paternal lineage., Conclusions: Finally, clinical history correlated to the different genotypes in the family, concluding that the severity of these VHL manifestations are due to both, VHL-and-CHEK2 mutations. This case report aims to notice the importance of deeper genetic analyses, in inherited rare diseases, to uncover non-expected mutations., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This research was funded by the Ministry of Science and Innovation of Spain (grant number PID2020-115371RB-I00)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Endothelial to mesenchymal transition in an HHT-like pediatric case of multiple pulmonary arteriovenous malformations

  • Lorente-Herraiz, Laura
  • Cuesta, Ángel M.
  • Recio-Poveda, Lucía
  • Botella, Luisa María
  • Albiñana, Virginia
15 p.-6 fig.-1 tab., Pulmonary arteriovenous malformations (PAVMs) are vascular anomalies resulting in abnormal connection between pulmonary arteries and veins. In 80% of cases, PAVMs are present from birth, but clinical manifestations are rarely seen in childhood. These congenital malformations are typically associated with Hereditary Hemorrhagic Telangiectasia (HHT), a rare disease that affects 1 in 5,000/8,000 individuals. HHT disease is frequently caused by mutations in genes involved in the TGF-β pathway. However, approximately 15% of patients do not have a genetic diagnosis and, among the genetically diagnosed, more than 33% do not meet the Curaçao Criteria. This makes clinical diagnosis even more challenging in the pediatric age group. Here, we introduce an 8 years old patient bearing a severe phenotype of multiple diffuse PAVMs caused by an unknown mutation which ended in lung transplantation. Phenotypically, the case of study follows a molecular pattern HHT-like. Therefore, molecular biology and cellular functional analysis has been performed in primary endothelial cells (ECs) isolated from the explanted lung. The findings revealed a loss of functionality in lung endothelial tissue and a stimulation of endothelial to mesenchymal transition. Understanding the molecular basis of this transition could potentially offer new therapeutic strategies to delay lung transplantation in severe cases., This research was funded by MICINN (Ministry of Science and Innovation of Spain), grant number PID2020-115371RB-I00., No
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Molecular and Cellular Characterization of Primary Endothelial Cells from a Familial Cavernomatosis Patient

  • Lorente-Herraiz, Laura
  • Cuesta, Ángel M.
  • Granado, Jaime
  • Recio-Poveda, Lucía
  • Botella, Luisa María
  • Albiñana, Virginia
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)., Cerebral cavernous malformation (CCM) or familial cavernomatosis is a rare, autosomal dominant, inherited disease characterized by the presence of vascular malformations consisting of blood vessels with an abnormal structure in the form of clusters. Based on the altered gene (CCM1/Krit1, CCM2, CCM3) and its origin (spontaneous or familial), different types of this disease can be found. In this work we have isolated and cultivated primary endothelial cells (ECs) from peripheral blood of a type 1 CCM patient. Differential functional and gene expression profiles of these cells were analyzed and compared to primary ECs from a healthy donor. The mutation of the familial index case consisted of a heterozygous point mutation in the position +1 splicing consensus between exons 15 and 16, causing failure in RNA processing and in the final protein. Furthermore, gene expression analysis by quantitative PCR revealed a decreased expression of genes involved in intercellular junction formation, angiogenesis, and vascular homeostasis. Cell biology analysis showed that CCM1 ECs were impaired in angiogenesis and cell migration. Taken together, the results obtained suggest that the alterations found in CCM1 ECs are already present in the heterozygous condition, suffering from vascular impairment and somewhat predisposed to vascular damage., This research was funded by the Ministry of Economy of Spain (MINECO), grant number SAF2017-83351R, and by the Ministry of Science and Innovation of Spain (MICINN), grant number PID2020-115371RB-I00. L.R.-P. was the recipient of a contract from an internal project of CSIC (PIE201820E073)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Endothelial-to-Mesenchymal Transition in an Hereditary Hemorrhagic Telangiectasia-like Pediatric Case of Multiple Pulmonary Arteriovenous Malformations

  • Lorente-Herraiz, Laura
  • Cuesta, Angel M.
  • Recio-Poveda, Lucía
  • Botella, Luisa María
  • Albiñana, Virginia
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)., Pulmonary arteriovenous malformations (PAVMs) are vascular anomalies resulting in abnormal connections between pulmonary arteries and veins. In 80% of cases, PAVMs are present from birth, but clinical manifestations are rarely seen in childhood. These congenital malformations are typically associated with Hereditary Hemorrhagic Telangiectasia (HHT), a rare disease that affects 1 in 5000/8000 individuals. HHT disease is frequently caused by mutations in genes involved in the TGF-β pathway. However, approximately 15% of patients do not have a genetic diagnosis and, among the genetically diagnosed, more than 33% do not meet the Curaçao criteria. This makes clinical diagnosis even more challenging in the pediatric age group. Here, we introduce an 8-year-old patient bearing a severe phenotype of multiple diffuse PAVMs caused by an unknown mutation which ended in lung transplantation. Phenotypically, the case under study follows a molecular pattern which is HHT-like. Therefore, molecular- biological and cellular-functional analyses have been performed in primary endothelial cells (ECs) isolated from the explanted lung. The findings revealed a loss of functionality in lung endothelial tissue and a stimulation of endothelial-to-mesenchymal transition. Understanding the molecular basis of this transition could potentially offer new therapeutic strategies to delay lung transplantation in severe cases., This research was funded by MICINN (Ministry of Science and Innovation of Spain), grant number PID2020-115371RB-I00. L.R.-P. was the recipient of a contract from an internal project of CSIC (PIE201820E073). L.L.-H is contracted by CIBER, focused on rare diseases (ISCIII, Spain)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Effect of 5β-dihydrotestosterone on vasodilator function and on cell proliferation

  • Sánchez Fernández, D.
  • Eguibar, Aritz
  • López, Cristina
  • Cuesta, Angel M.
  • Albiñana, Virginia
  • Rogers-Ezewuike, Soline
  • Gómez-Rivas, Juan
  • Saldaña, Laura
  • Botella, Luisa María
  • Ferrer Parra, Mercedes
18 p.-7 fig., Aging is one of the main factors associated with cardiovascular diseases. Androgens exert beneficial effects on the cardiovascular system and testosterone (TES) replacement therapy improves cardiometabolic risk factors. However, TES is contraindicated in patients with prostate cancer due to its proliferative effects on prostatic tumor cells. Additionally, TES and its reduced metabolites 5α- and 5β-dihydrotestosterone (5α-DHT and 5β-DHT) exert vasodilatory effects. Since androgen levels decrease during aging and 5β-DHT lacks genomic effects, this study is focused on analyzing its effect on vasodilator function and the proliferation rate of prostatic tumor and vascular smooth muscle cells. To study the vascular function, mesenteric arteries from aged-orchidectomized Sprague-Dawley rats were used. Mesenteric segments were divided into one control (without treatment) and three groups with the androgens (10 nM, 30 min) to analyze: acetylcholine- and sodium nitroprusside-induced responses and nitric oxide and superoxide anion production. To analyze cell proliferation, the effect of androgens on cell viability was determined. The results showed that 5β-DHT improves vasodilator function in arteries from aged-orchidectomized rats and induces antioxidant action, while the proliferation rate of the androgen-dependent prostatic tumor cells remains unaltered. These results make 5β-DHT a promising therapeutic agent for the treatment of cardiovascular pathologies., This study was supported by a grant from the Instituto de Salud Carlos III (PI19/01282) and Fondo Europeo de Desarrollo Regional to M. Ferrer, and a grant from the Ministry of Science and Innovation of Spain (PID2020-115371RB-I00) to L.M. Botella, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Targeting aggressive VHL disease with a germinal mutation in the CHEK2 gene: A personalized approach

  • Albiñana, Virginia
  • Sarro Miguel, Clara
  • Lorente-Herraiz, Laura
  • Recio-Poveda, Lucía
  • Cuesta, Ángel M.
  • Viñas-López, Jesús
  • Aguirre, Daniel T.
  • Ruiz-Llorente, Lidia
  • Botella, Luisa María
13 p.-5 fig.-1 tab., Background: Von Hippel-Lindau (VHL) is a rare inherited dominant disorder leading to central nervous system hemangioblastomas, clear cell renal carcinoma, pheochromocytoma, and pan-creatic tumors. It affects 1 in 36,000 births, VHL patients are heterozygous for a pathogenic VHL mutation in germline. A second mutation in the other allele is required for tumor development, resulting in loss of pVHL function, responsible for degradation of Hypoxia-Inducible Factor (HIF) under normoxia. Without pVHL, HIF translocates into nucleus, inducing targets of the hypoxia program, among them genes involved in proliferation and angiogenesis. VHL disease shows variable phenotypic manifestations and different severity. A previous study analyzed a severe case of VHL with an unusually early onset and aggressive progression, carrying a heterozygous Check2 mutation., Methods: Cell cultures from three surgeries of this patient were analyzed, revealing complete loss of pVHL and multiple somatic mutations in different tumor cells. Using the “Pandrugs” algorithm as a predictive tool and inputting VHL and CHEK2 as the mutated genes, Olaparib was identified as the most suitable therapeutic option. Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor., Results: In vitro, olaparib reduced cell viability by 50%, moreover combined with ICI-118,551, a beta-adrenergic receptor blocker, viability was re-duced by 80%, showing an additive effect. Conclusions: These findings highlight the role of personalized medicine showing how tailored treatments can improve clinical outcomes., This research was funded by MICINN (Ministry of Science and Innovation of Spain), grant AEI/10.13039/501100011033 number PID2020-115371RB-I00 by FEDER and MICINN grant AEI number PID2023-146593OB-I00., Peer reviewed
Docta Complutense
Publication Artículo científico (JournalArticle)

Molecular and Cellular Characterization of Primary Endothelial Cells from a Familial Cavernomatosis Patient

  • Lorente-Herraiz, Laura
  • Cuesta Martínez, Ángel
  • Granado, Jaime
  • Recio-Poveda, Lucía
  • Botella, Luisa-María
  • Albiñana, Virginia
Cerebral cavernous malformation (CCM) or familial cavernomatosis is a rare, autosomal dominant, inherited disease characterized by the presence of vascular malformations consisting of blood vessels with an abnormal structure in the form of clusters. Based on the altered gene (CCM1/Krit1, CCM2, CCM3) and its origin (spontaneous or familial), different types of this disease can be found. In this work we have isolated and cultivated primary endothelial cells (ECs) from peripheral blood of a type 1 CCM patient. Differential functional and gene expression profiles of these cells were analyzed and compared to primary ECs from a healthy donor. The mutation of the familial index case consisted of a heterozygous point mutation in the position +1 splicing consensus between exons 15 and 16, causing failure in RNA processing and in the final protein. Furthermore, gene expression analysis by quantitative PCR revealed a decreased expression of genes involved in intercellular junction formation, angiogenesis, and vascular homeostasis. Cell biology analysis showed that CCM1 ECs were impaired in angiogenesis and cell migration. Taken together, the results obtained suggest that the alterations found in CCM1 ECs are already present in the heterozygous condition, suffering from vascular impairment and somewhat predisposed to vascular damage.
Docta Complutense
Publication Artículo científico (JournalArticle)

Mutation in Chek2 triggers von Hippel-Lindau hemangioblastoma growth

  • Cabrera-Montes, Jorge
  • Aguirre, Daniel T.
  • Viñas-López, Jesús
  • Lorente-Herraiz, Laura
  • Recio-Poveda, Lucía
  • Albiñana, Virginia
  • Julián Pérez-Pérez
  • Botella, Luisa M.
  • Cuesta Martínez, Ángel
Purpose: Von Hippel-Lindau (VHL) is a rare inherited disease mainly characterized by the growth of tumours, predominantly hemangioblastomas (Hbs) in the CNS and retina, and renal carcinomas. The natural history of VHL disease is variable, differing in the age of onset and its penetrance, even among relatives. Unfortunately, sometimes VHL shows more severe than average: the onset starts in adolescence, and surgeries are required almost every year. In these cases, the factor that triggers the appearance and growth of Hbs usually remains unknown, although additional mutations are suspected. Methods: We present the case of a VHL patient whose first surgery was at 13 years of age. Then, along his next 8 years, he has undergone 5 surgeries for resection of 10 CNS Hbs. To clarify this severe VHL condition, DNA from a CNS Hb and white blood cells (WBC) was sequenced using next-generation sequencing technology. Results: Massive DNA sequencing of the WBC (germ line) revealed a pathogenic mutation in CHEK2 and the complete loss of a VHL allele (both tumour suppressors). Moreover, in the tumour sample, several mutations, in BRAF1 and PTPN11 were found. Familiar segregation studies showed that CHEK2 mutation was in the maternal lineage, while VHL was inherited by paternal lineage. Conclusions: Finally, clinical history correlated to the different genotypes in the family, concluding that the severity of these VHL manifestations are due to both, VHL-and-CHEK2 mutations. This case report aims to notice the importance of deeper genetic analyses, in inherited rare diseases, to uncover non-expected mutations.